Thursday, August 14, 2025

CH10: READING BETWEEN THE ECHOES


THE EYE WITHIN

UNLOCKING THE HIDDEN LANGUAGE OF MEDICAL IMAGING

By: Lennard M. Goetze, Ed.D  

In an age when medical imaging technologies grow more advanced by the day, one truth remains unchanged: a scan is only as valuable as the mind interpreting it. The Eye Within pulls back the curtain on the art and science of diagnostic interpretation through the career and insights of Dr. Robert Bard—internationally recognized cancer imaging specialist, educator, and pioneer in ultrasound diagnostics.

This is not a book about machines; it is about mastery. Dr. Bard takes readers into the high-stakes environment of medical imaging, where detecting a shadow, reading a flow pattern, or recognizing a subtle shift in tissue texture can change a life. With clarity and precision, he explains how ultrasound—when wielded by an experienced interpreter—becomes more than a tool for capturing anatomy. It becomes a dynamic instrument for understanding disease behavior, predicting progression, and guiding treatment.

From evaluating elusive thyroid disorders to identifying aggressive cancers others might miss, Dr. Bard demonstrates the power of seeing beyond the image. His work exemplifies how structural detail, physiologic clues, and contextual patient information combine into a complete diagnostic picture. At its heart, The Eye Within is both an education and a call to action—urging the medical community to value interpretation as a central pillar of care. For clinicians, students, and health advocates, it is a masterclass in precision medicine. For patients, it is reassurance that in the right hands, every image tells a story—and the right interpreter knows exactly how to read it. 

 

Copyright © 2025- Hummingbird Medical Press / Lennard Goetze Publications. All rights reserved.



Sample Chapter:

READING BETWEEN THE ECHOES

Dr. Bard Interprets Thyroid Ultrasound

 

Introduction – The Eye That Reads Beyond the Image

In the evolving landscape of diagnostic imaging, technology has made breathtaking advances. Yet, as Dr. Robert Bard often reminds all his colleagues, “It’s not the probe, but the interpreter, that saves the patient.”

Ultrasound has become a preferred frontline tool for thyroid evaluation, particularly for identifying nodules, monitoring autoimmune conditions like Hashimoto’s disease, and managing hyperactive disorders such as Graves disease. But while many can operate the machine, very few can translate its subtle, often cryptic language into decisive clinical insight. Dr. Bard is one of those few—a master “ultrasound translator” who sees patterns, behaviors, and evolving risks invisible to most.

This observational session—built on a series of ten thyroid ultrasound slides provided by Dr. Angela Mazza—offers a rare glimpse into the process of real-time interpretation. Six images focus on thyroid nodules; the remaining highlight hallmark features of Hashimoto’s thyroiditis and Graves disease. As Dr. Bard examines each slide, he performs not merely an identification exercise, but an on-time analysis: assessing the surrounding anatomy, interpreting vascular and tissue signatures, and predicting potential outcomes.

Even in an era of AI-assisted imaging, this skill remains irreplaceable. Artificial intelligence can catalog shapes and colors, but it cannot yet replicate the human ability to weigh anatomical nuance, integrate patient history, evaluate the tumor’s ecosystem, and make forward-looking predictions. Interpretation—true interpretation—blends technology, clinical reasoning, and physiological understanding.


What follows are Dr. Bard’s own notes, presented in the first person, refined for clarity and depth, reflecting his approach as both a diagnostician and educator.

Assessment 1: NODULES

 

Click to enlarge
Solid Growth Without Suspicious Calcifications

I begin with the skin layer clearly visible at the top, followed by the anterior neck musculature and, deeper, the thyroid itself. The lesion’s borders are smooth—always a favorable sign—and I see no suspicious microcalcifications. While microcalcifications are nonspecific, their presence can indicate tissue degeneration from rapid tumor growth and poor vascular supply. Here, the echo pattern is heterogeneous, meaning the texture varies within the nodule, which warrants closer review. Of particular academic interest is the posterior wall brightness—dimmer than the anterior—reflecting sound absorption by solid tissue. This “through transmission” loss can signal dense or heterogeneous pathology and is an important interpretive clue.

 

Click to enlarge
Simple Cyst with High Through Transmission

This image shows a well-circumscribed, cystic structure. The posterior border is brighter than the anterior because fluid allows sound to pass freely. Internal debris is visible—common in benign cysts and observable with high-resolution probes. Surrounding tissues are neither compressed nor invaded, suggesting no aggressive behavior. This is a prime example of strong through transmission, a useful differentiator between cystic and solid pathology.


Click to enlarge
Partially Cystic Complex Nodule
This lesion exhibits both solid and cystic components, the most common benign thyroid pattern but also possible in malignancies. The posterior border is again brighter due to the fluid component. On the left, I note the common carotid artery—its wall smooth and without plaque. When scanning thyroids, I always evaluate adjacent structures; lymph nodes and vessels often provide indirect clues to pathology.



Click to enlarge
Predominantly Solid Complex Nodule with Early Calcification

Here, the anterior and posterior borders are similar in brightness, suggesting limited fluid content. The heterogeneous echo texture and a small calcification at the cystic-solid interface may represent tumor degeneration. It’s important to remember that tumor enlargement during therapy does not always indicate progression—degenerating tumors can swell with fluid before shrinking.


 

 

Click to enlarge
Septated Complex Nodule with Macrocalcification

The lesion contains cystic and solid areas separated by septations, giving it a spongiform appearance. The macrocalcification is consistent with degenerative change. The bright posterior border confirms significant cystic degeneration—what I refer to as “internal cystic necrosis”—often a sign of tumor breakdown.

 


Assessment #2:  
THYROID CANCER    

 

Click to enlarge
Classic Ultrasound Signatures of Thyroid Cancer

In this case, credit must be given to Dr. Angela Mazza for her precise capture of a lesion demonstrating classic hallmarks of thyroid cancer. High-quality image acquisition is not accidental—it reflects an operator’s ability to optimize probe selection, angulation, and focal depth to reveal the lesion’s most telling features. This provides the interpreting radiologist with the complete visual data needed for an accurate assessment. One such feature is the presence of microcalcifications—tiny, punctate echogenic foci within the lesion. While not exclusively diagnostic of cancer, their occurrence often signals abnormal cellular turnover and tissue degeneration, making them an important red flag in the radiologist’s assessment.

A second hallmark is the firm, rigid texture of malignant tissue. I often describe it to students using the “steel analogy”: just as steel resists penetration, cancerous tissue offers a gritty, unyielding resistance to a biopsy needle. This hardness correlates with the tumor’s dense cellular structure and fibrotic reaction. Equally significant is the taller-than-wide dimension ratio. Benign nodules, when they grow, tend to expand laterally, developing smooth, encapsulated borders. Aggressive cancers, however, often invade vertically, crossing tissue planes. This vertical dominance is a subtle but critical diagnostic cue—used not only in thyroid cancer but also in breast oncology.

On ultrasound, malignancies typically appear hypoechoic—darker than the surrounding thyroid parenchyma—because the dense cellular mass absorbs more sound energy, allowing less to be reflected back to the transducer. This also results in a posterior acoustic shadow or a dimmer back border, further reinforcing the suspicion of a solid, infiltrative process. When these elements—microcalcifications, firmness, hypoechogenicity, vertical growth, and diminished posterior transmission—are observed together, they form a constellation of findings that strongly favor malignancy. The role of the interpreting radiologist is not simply t note these features, but to integrate them into a complete risk profile for each patient, guiding both urgency and strategy in clinical management.

 

Assessment 3: HASHIMOTO’S & GRAVES DISEASE

 

Click to enlarge
Hashimoto’s Thyroiditis

Hashimoto’s presents variably on ultrasound—sometimes uniform in echotexture, sometimes showing fibrotic stranding and mixed internal patterns. Routine thyroid blood panels can miss autoimmune-mediated inflammation, making ultrasound a critical adjunct. The gland may reveal fibrotic bands, patchy echogenic change, or small cystic areas depending on the stage of degeneration. In this case, the echo pattern is mixed, with no significant change in rear-wall brightness compared to normal thyroid tissue. Because through-transmission may remain unaltered, interpretation must be integrated with autoimmune-specific serology, patient symptoms, and disease history to achieve a confident diagnosis and guide long-term management.

 

 

Graves

Click to enlarge
Disease: Baseline B-Mode & with Color Doppler

Although Graves’ disease is not a form of cancer, it remains a significant thyroid condition because of its system-wide effects and marked increase in glandular blood flow. The overproduction of thyroid hormones accelerates metabolism across multiple organ systems, influencing cardiovascular function, skin changes, and general physiological balance. In grayscale (B-mode) ultrasound, the thyroid often presents with a uniform appearance, though areas of patchy irregularity from fibrotic change may be visible. Through-transmission typically mirrors that of normal tissue; however, the clearest diagnostic distinction emerges when color Doppler imaging is applied.

 

Under Doppler, Graves’ disease can display a pronounced surge in intrathyroidal vascularity, with smooth, branching blood vessels feeding an overactive gland. This striking visual signature—sometimes described as a “thyroid inferno”—serves not only as an identifier of disease activity but also as a guide for therapy. By following these vascular patterns over time, clinicians can fine-tune treatment plans and adjust dosages without invasive biopsies or radioactive scans.

 

 

THERMOLOGY: THE STRATEGIC FIRST STEP IN THYROID IMAGING

Before an ultrasound probe touches the skin, thermographic imaging can create a dynamic map of the thyroid’s physiologic activity. By detecting infrared heat patterns from the skin surface, thermology reveals areas of abnormal vascular activity—whether from inflammation, autoimmune flare, or tumor-driven angiogenesis. This non-contact, radiation-free technique serves as an early “scout,” directing the sonographer’s focus to regions most likely to harbor disease.

 

When paired with ultrasound, thermology’s surface heat mapping complements sonography’s deeper structural view. Elevated heat zones may correspond to hypervascular nodules in Graves’ disease or inflammatory patterns in Hashimoto’s, while cooler areas may signal cystic or fibrotic changes. Beyond detection, thermal assessment can monitor treatment response—declines in both vascularity and gland temperature often indicate therapy is working. 

In skilled hands, this dual-modality approach—thermology for physiologic mapping and ultrasound for structural definition—offers a fast, noninvasive, and highly precise pathway for diagnosis, monitoring, and personalized thyroid care.

 

CONCLUSION – A PARTNERSHIP IN PRECISION

Dr. Bard’s review of Dr. Angela Mazza’s thyroid ultrasound cases demonstrates why expertise in interpretation remains indispensable. Every scan is more than an image—it is a layered narrative of structure, function, and evolving physiology. By coupling her deep endocrinology expertise with ultrasound as a primary diagnostic tool, Dr. Mazza ensures her patients receive assessments that are both scientifically rigorous and dynamically responsive.

In an age where algorithms threaten to overshadow human judgment, this collaboration underscores an enduring truth: the best outcomes emerge when skilled imaging interpretation meets the informed clinical context of a specialist who understands the whole patient.

 

 

INTRADERMAL SCAN: 8-14

Sunday, June 29, 2025

INTRODUCING LYMESCAN™


 Advanced Diagnostic & Therapeutic Care for Lyme and Vector-Borne Illness

Lyme disease and its associated co-infections remain among the most misunderstood and underdiagnosed health crises of our time. Patients suffering from persistent fatigue, cognitive decline, joint pain, neurological shifts, or autoimmune symptoms often endure years of misdiagnoses and ineffective treatments.


THE PROBLEM WITH LYME: WHY STANDARD CARE OFTEN FALLS SHORT

Conventional Lyme diagnostics rely heavily on outdated, insensitive tests and rigid definitions of disease progression. Most physicians are trained to recognize only early-stage Lyme through the presence of a rash or acute symptoms—missing the widespread reality of chronic or “hidden” infections that persist long after exposure.

Dr. Letitia’s research and clinical work have consistently revealed that Borrelia (the Lyme bacterium) can evade both the immune system and conventional detection by transforming into cystic forms or embedding in biofilms. Co-infections such as Bartonella and Babesia further complicate diagnosis, often manifesting as psychiatric symptoms, autoimmune markers, or nonspecific inflammation.

LYMESCAN addresses this diagnostic gap—combining advanced ultrasound imaging with deep clinical evaluation to deliver precise, personalized, and timely care.


WHAT MAKES LYMESCAN DIFFERENT?

1. Precision Imaging by Dr. Bard

Using high-resolution Doppler and elastography ultrasound, Dr. Bard brings cutting-edge tools to visualize signs of infection-related inflammation, tissue damage, vascular changes, and subdermal abnormalities often missed in standard evaluations. Imaging areas like joints, skin, lymph nodes, and soft tissues allows for real-time insights into where and how pathogens may be affecting the body.

 

2. Expert Clinical Investigation by Dr. Letitia

Dr. Letitia conducts a comprehensive clinical workup, including an exhaustive history of symptoms, prior exposures, travel, co-infections, mold exposure, immune history, and viral reactivations. Her protocols go beyond checklists—integrating molecular testing, immune panels, and even therapeutic “challenge” regimens to uncover hidden infections.

 

3. Whole-Person Diagnostic Strategy

Where most practices stop at lab reports, LYMESCAN investigates the full story. By combining clinical intuition, advanced imaging, and laboratory diagnostics, the program addresses both active infections and the systemic aftermath of past disease—empowering each patient with answers tailored to their physiology.


To be continued:


The Hormonal Havoc of Lyme Disease:
A Diagnostic Dilemma

Lyme disease often presents with subtle and nonspecific symptoms that can complicate timely diagnosis, which leads to patient frustration on many levels. Early signs may include fatigue, brain fog, joint pain, mood changes, and disrupted sleep—symptoms that can easily be mistaken for lots of conditions - ie. stress, hormone imbalance, or autoimmune disorders. Compounding the challenge, standard testing methods such as ELISA and Western blot may lack sensitivity in early or chronic stages, leading to false negatives. From an endocrine standpoint, Lyme disease can provoke systemic inflammation and immune dysregulation, disrupting the hypothalamic-pituitary-adrenal (HPA) axis. This chronic inflammatory state may alter cortisol rhythms, impair thyroid function, and contribute to estrogen and progesterone imbalances, particularly in women. Such endocrine disruptions can further perpetuate fatigue, anxiety, menstrual irregularities, and cognitive dysfunction, creating a complex clinical picture that blurs the lines between infectious, autoimmune, and hormonal conditions.  Having better and earlier strategies for diagnosis is not only important, it is essential!


FROM THE FRONT LINES

As the Northeast enters its annual tick season—typically from April through September—residents face heightened risk of Lyme disease, transmitted by blacklegged ticks (Ixodes scapularis). A Dartmouth meta‑analysis found that approximately 50% of adult deer ticks in Northeastern states such as New York, Connecticut, New Hampshire, Vermont, and Maine harbor Borrelia burgdorferi, with infection rates in nymphs reaching up to 25%.  Nymphs, though smaller and often overlooked, are responsible for most human transmissions during late spring and early summer .


In 2023, the Centers for Disease Control recorded over 89,000 reported Lyme cases nationwide, with the Northeast and Mid‑Atlantic accounting for nearly all high‑incidence regions cdc.gov / epa.gov  With these realities in mind, LYMESCAN’s integrated diagnostic and therapeutic program is both timely and essential, offering advanced imaging, expert clinical insight, and mental‑health support tailored for those navigating this complex public‑health challenge.



 

WHO IS LYMESCAN FOR?

·   Individuals with persistent, unexplained symptoms including fatigue, brain fog, joint pain, or neuropathy

·   Patients previously treated for Lyme disease who suspect relapse or co-infection

·   Individuals misdiagnosed with autoimmune or psychiatric conditions but suspect an infectious trigger

·   Families seeking care for children with sudden behavioral, mood, or developmental changes

·   People with known mold exposure, long COVID, or immune dysfunction who now suffer new symptoms

 

 

MORE THAN DIAGNOSIS: A PATH FORWARD

At LYMESCAN, we believe every patient deserves more than a label. Our mission is to empower individuals through knowledge, validation, and targeted care. Through our partnership, Dr. Letitia provides integrative therapeutic strategies, including immune modulation, detoxification support, herbal and pharmaceutical antimicrobials, and guidance on lifestyle changes to restore systemic balance. Dr. Bard contributes ongoing imaging feedback to monitor treatment response, catch early relapses, and guide next steps.

 

 

THE NEXT GENERATION OF LYME CARE IS HERE

Whether you are still searching for answers, or seeking more advanced tools after incomplete treatments elsewhere, LYMESCAN offers a smarter, science-driven solution. Our program is built for the patients that others overlook—because we believe no one should have to suffer in the shadows.

 

 

LYME DISEASE EDUCATION: EMPOWERING THROUGH UNDERSTANDING

At LYMESCAN™, education is at the heart of healing. We believe that patients, caregivers, and healthcare providers alike deserve accurate, up-to-date knowledge about Lyme disease and the broader landscape of vector-borne infections.

Lyme disease is not just a rash and joint pain—it is a complex, evolving illness that can affect the brain, heart, nervous system, and immune response. It can mimic conditions such as chronic fatigue syndrome, multiple sclerosis, depression, and autoimmune disorders. Many patients are left misdiagnosed or untreated simply because practitioners are unaware of the disease’s chronic and multifaceted nature.

Through educational seminars, practitioner outreach, and patient resources, LYMESCAN is committed to raising awareness about:

·   The biology of Borrelia and its ability to evade immune detection

·   Co-infections like Bartonella, Babesia, and Anaplasma that alter disease progression

·   The role of biofilms, cystic forms, and immune suppression in chronic illness

·   Modern tools for accurate diagnosis and symptom monitoring

·   The importance of early detection and comprehensive care

We strive to close the knowledge gap and empower every patient with the facts they need to advocate for their health. Education isn’t optional—it’s essential.


MEET THE LYMESCAN™ TEAM

Uniting Innovation, Clinical Precision, and Compassionate Mental Health Care

LYMESCAN™ brings together a powerhouse team of medical professionals with a shared mission: to transform the way Lyme disease and chronic infections are diagnosed, understood, and treated.

Dr. Robert L. Bard is a globally recognized authority in advanced diagnostic imaging. With decades of experience in functional ultrasound, elastography, and vascular analysis, Dr. Bard is at the forefront of identifying subclinical inflammation, tissue abnormalities, and infectious footprints. His noninvasive imaging strategies bring clarity to complex conditions—offering real-time visuals that validate symptoms and guide precision care.

Dr. Jennifer Letitia is a distinguished integrative physician renowned for her expertise in chronic Lyme disease, mold toxicity, post-viral syndromes, and immune dysregulation. Known for her methodical, whole-body evaluations, Dr. Letitia combines clinical intuition with deep diagnostic science to uncover the root causes of unexplained illness. Her protocol blends advanced testing, symptom-based analysis, and therapeutic interventions grounded in both conventional and naturopathic medicine.

Dr. Barbara Bartlik completes the triad as an esteemed integrative psychiatrist and functional mental health specialist. With vast experience in trauma-informed care, neuropsychiatry, and mind-body medicine, Dr. Bartlik addresses the emotional and cognitive toll of chronic illness. From depression and anxiety to Lyme-induced neurological symptoms, she helps patients restore emotional resilience and psychological balance while working in tandem with the medical team.

Together, this interdisciplinary alliance delivers a truly 360-degree model of care, ensuring no symptom is dismissed and no patient is left behind.

Book a LYMESCAN consultation today and take your first step toward true healing. Clinical appointments available in-person or via referral. For more information, visit www.LymeScan.org





Exploring the Link Between Lyme Disease and Hashimoto’s Thyroiditis

The Overlap of Autoimmunity, Infection, and Diagnostic Innovation

Emerging research points to a potential relationship between Lyme disease—a tick-borne infection caused by Borrelia burgdorferi—and Hashimoto’s thyroiditis, an autoimmune disorder in which the immune system mistakenly targets the thyroid gland. Though the link is still being actively investigated, multiple clinical observations suggest that chronic infections like Lyme may play a role in triggering or aggravating autoimmune thyroid dysfunction.

Lyme Disease as a Potential Autoimmune Trigger

Lyme disease can initiate a strong immune response that, in genetically susceptible individuals, may contribute to the onset of autoimmune conditions. Some researchers propose that the body’s attempt to combat the Borrelia infection may inadvertently set off inflammatory or autoimmune processes, potentially including Hashimoto’s (Klempner et al., 2001).

Molecular Mimicry: A Case of Mistaken Identity

One of the most discussed theories is molecular mimicry, where the immune system confuses the proteins of the Lyme bacteria with those of the thyroid gland. This cross-reactivity may cause the immune system to attack thyroid tissue, mistaking it for an infectious threat (Chmielewska-Badora et al., 2000).

Symptom Confusion

Both Hashimoto’s and chronic Lyme disease present with overlapping symptoms—fatigue, cognitive dysfunction (“brain fog”), joint stiffness, depression, and cold sensitivity—making it difficult to discern one condition from the other without careful investigation. Misdiagnosis or delayed diagnosis is common when symptom patterns blur the lines between infection and autoimmunity (Stricker & Fesler, 2018).

Systemic Inflammation and Hormonal Disruption

Lyme disease can generate widespread inflammation that disrupts endocrine function. The thyroid, being highly sensitive to immune signals, may respond to this inflammation with impaired hormone production. Additionally, systemic infections can throw off hormonal feedback loops, contributing to thyroid irregularities or exacerbating existing autoimmune responses (Rapoport, 2012).


The Role of Ultrasound in Diagnosis and Monitoring

Thyroid ultrasound imaging has become an essential, non-invasive tool in evaluating the thyroid gland in both Hashimoto’s and Lyme-related presentations. High-resolution ultrasound can detect structural changes in the thyroid—such as tissue heterogeneity, gland enlargement, or nodules—that may be missed by standard blood tests alone.

In patients with suspected autoimmune thyroiditis or lingering inflammatory symptoms following Lyme exposure, ultrasound offers valuable real-time insights into the condition of the thyroid tissue. Specific signs such as reduced echogenicity (indicating inflammation), irregular margins, or altered vascular patterns can help support a diagnosis of Hashimoto’s or flag abnormalities that warrant further investigation (Iannuccilli et al., 2004).

In advanced integrative practices, ultrasound is also used for tracking disease progression, evaluating treatment response, and distinguishing between autoimmune damage and other thyroid-related pathologies. It is especially useful in individuals who present with persistent symptoms despite normal lab results—providing a visual validation of subclinical or silent inflammation.


Key Clinical Considerations

·        Evolving Science: While a causal link between Lyme disease and Hashimoto’s has not yet been definitively established, the immunological interplay is gaining more attention in clinical circles. More longitudinal and molecular studies are needed to confirm this relationship.

·        Diagnostic Strategy: For patients with a Hashimoto’s diagnosis and a history of tick exposure or chronic systemic symptoms, clinicians may consider expanded testing for Lyme disease and incorporate thyroid ultrasound as part of a comprehensive assessment.

·        Treating the Root: Functional and integrative medicine practitioners often look beyond symptom management to identify infectious, toxic, or inflammatory contributors to autoimmune dysfunction. Addressing potential Lyme infections may support thyroid recovery and symptom reduction in select patients.




AFTERTHOUGHT: A NOTE TO CARE STRATEGISTS
By: Dr. Angela Mazza - Integrative Endocrinologist

Lyme disease patients can be a challenging patient group - without a doubt!  Chronic infections like Lyme disease may act as environmental triggers for autoimmunity through mechanisms such as molecular mimicry, immune system dysregulation, and persistent inflammation. In certain genetically predisposed individuals, the immune response to Borrelia may cross-react with thyroid antigens such as thyroid peroxidase (TPO), promoting the production of thyroid autoantibodies and eventual thyroid tissue damage. Also, this chronic immune activation, that is often seen in post-treatment Lyme disease syndrome (PTLDS), may contribute to a Th1-dominant immune profile, which is frequently associated with autoimmune thyroid conditions. As clinicians, we should consider autoimmune thyroid screening in patients with persistent symptoms after Lyme disease, especially fatigue, cold intolerance, or weight gain, which overlap with hypothyroid presentations.




References

·        Chmielewska-Badora, J., Cisak, E., Wójcik-Fatla, A., ZwoliÅ„ski, J., & Dutkiewicz, J. (2000). Lyme borreliosis and autoimmune diseases. Annals of Agricultural and Environmental Medicine, 7(2), 183–186.

·        Iannuccilli, J. D., Cronan, J. J., & Monchik, J. M. (2004). Risk for malignancy of thyroid nodules as assessed by sonographic criteria: The need for biopsy. Journal of Ultrasound in Medicine, 23(11), 1455–1464.

·        Klempner, M. S., Hu, L. T., Evans, J., Schmid, C. H., Johnson, G. M., Trevino, R. P., ... & Weinstein, A. (2001). Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. New England Journal of Medicine, 345(2), 85–92.

·        Rapoport, B. (2012). Mechanisms of autoimmunity in Graves’ disease and Hashimoto’s thyroiditis. Endocrinology and Metabolism Clinics, 41(4), 849–860.

·        Stricker, R. B., & Fesler, M. C. (2018). Chronic Lyme disease: A working case definition. Chronic Diseases International, 5(1), 1–6.

 

 

 

 

Monday, June 2, 2025

Dr. Robert Bard Leads a Diagnostic Revolution: Fusing Thermography and Ultrasound to Detect Disease Without Biopsies

Introduction:
In the heart of Midtown Manhattan, diagnostic imaging is being reimagined by one of the field’s most innovative minds. Dr. Robert Bard, a seasoned radiologist and founder of Bard Diagnostic Imaging, is reshaping the standard of care through a pioneering integration of medical thermography and diagnostic ultrasound. Described as a “medical detective,” Dr. Bard is championing the use of non-invasive technologies to replace painful and often unnecessary biopsies—offering patients a faster, safer, and more comprehensive diagnostic experience.

Integrative Imaging in Action: Thermography as the First Line of Defense
Dr. Bard begins his diagnostic process using thermal imaging—a modality that detects heat patterns and blood flow changes in the body. These colorful, high-resolution scans have become invaluable tools in identifying abnormalities that might be missed by traditional lab tests or physical exams.

“What we do is a thermogram to find the area that's suspicious,” explained Dr. Bard. “Then we go right to diagnostic ultrasound to see what's really going on.” In one example, thermal imaging revealed a temperature asymmetry in a patient’s thyroid. The darker hue on one side indicated poor blood flow, suggesting the presence of fibrosis or a cyst—something completely overlooked in prior lab work.


Ultrasound: Precision Validation That Prevents Unnecessary Procedures
Once thermography flags a potential issue, Dr. Bard transitions immediately to ultrasound imaging for confirmation. Using real-time, high-resolution scans, he was able to verify the presence of fibrotic scarring consistent with chronic thyroid disease. This insight allowed for prompt treatment with thyroid hormone therapy—without the need for an invasive biopsy.

“This will avoid a biopsy because now you can treat the patient based on what we see,” said Dr. Bard. “This is what real precision medicine looks like.”

A Grateful Patient, A Life-Altering Discovery
Patient Roberta Morris, who had long sought answers about her symptoms, expressed deep gratitude for the discovery. “This is a non-invasive way, so that’s the better way,” she said. “None of my other doctors ever suggested this, and today we confirmed that there really is an issue with my thyroid. I’m very grateful that it was caught early.”

Revealing What Others Miss: Breast Cancer and Thyroid Scarring
Dr. Bard's practice is filled with case studies that affirm the diagnostic power of thermal imaging. In one instance, thermography detected a malignant tumor that had been missed by mammography. In another, it revealed thyroid scarring that went undiagnosed until it was too late. “This is a way of looking at disease non-invasively,” said Dr. Bard. “We can see if a patient really needs a biopsy—or if they don’t.”

Despite its success, thermography remains underutilized in the United States due to a lack of insurance coverage. Nevertheless, Dr. Bard continues to advocate for its role in preventive care and integrative diagnostics.


Conclusion: A Visionary in the New Era of Diagnostic Imaging
With hundreds of documented successes and a growing international following, Dr. Robert Bard stands at the forefront of a new era in diagnostic medicine. His innovative fusion of thermography and ultrasound is not only redefining clinical protocols but also offering patients a gentler, smarter path to answers. As healthcare moves toward more personalized and non-invasive approaches, Dr. Bard’s contributions are proving to be nothing short of revolutionary.

___________________________________________________________________________________

Reclaiming Midlife Health: A Call for Modern, Intuitive Women’s Care                                 

By: Roberta Morris / Edited by: Lennard Goetze, Ed.D & Graciella Davi


Introduction: A Personal Wake-Up Call
I didn’t set out to rethink the state of women’s healthcare—I simply booked a diagnostic visit. What I found, however, was more than a medical evaluation. During a recent appointment with Dr. Robert Bard, a radiologist in New York known for his integrative approach, I encountered something rare: a provider who views the body as a system, the patient as a partner, and technology as a means to deeper understanding—not just a tool for confirming disease.

The visit was revealing in more ways than one. Through non-invasive Doppler imaging, Dr. Bard identified irregularities in my thyroid—an organ that had never been examined closely in my past checkups. But what stood out wasn’t just the technology. It was the philosophy. It was the understanding that midlife health, especially for women, can—and must—be treated with greater precision, respect, and foresight.

Section I: Midlife Health Isn’t a Footnote—It’s a Frontier
Midlife for women brings transformation on nearly every physiological level. And yet, mainstream medicine too often treats menopause as a short-term inconvenience, rather than a long-term hormonal shift that affects cardiovascular health, brain function, bone density, immune response, and more.

The common narrative is reductionist: treat the symptoms, ignore the source. Hot flashes? Try hormone therapy or tough it out. Fatigue? Probably just stress. Weight gain? Eat better. Rarely is a deeper investigation pursued—one that considers how estrogen decline impacts every cell in the body. For millions of women, this fragmented care leads to misdiagnoses, untreated conditions, and a loss of trust in the healthcare system.

Section II: Beyond Band-Aids—A Blueprint for Better Care
Dr. Bard’s practice, though singular, provides a model worth emulating. By applying functional medicine principles—early detection, systems thinking, and individualized care—he demonstrates how modern medicine can evolve without abandoning science.

At his facility, technology is used not just to diagnose, but to understand. Tools like Doppler ultrasound can catch thyroid irregularities or vascular concerns before symptoms manifest. This isn’t just innovation for innovation’s sake; it’s a quiet revolution in how we define “preventative care.”

The real lesson from my visit wasn’t about one practitioner’s brilliance. It was about what happens when care is curious, not just clinical—when a provider asks why something is happening, not just what.

Section III: Intuition, Empathy, and the Future of Women’s Health
What women in midlife need isn’t more prescriptions—they need more precision, more listening, and more leadership from providers who understand the nuances of female physiology. Care must be both holistic and high-tech. It must account for how lifestyle, environment, and genetics converge.

That requires training. It requires mentorship. It requires more providers like Dr. Bard—but more importantly, it requires that we learn from such models and push for systemic upgrades. Women shouldn’t have to stumble into exceptional care. It should be the standard.


Conclusion: Midlife as a Catalyst for Change
My appointment with Dr. Bard opened my eyes—not just to the state of my thyroid, but to the broader state of women’s healthcare. It exposed gaps I didn’t know existed and illuminated what’s possible when care is deeply human and deeply informed.

Midlife doesn’t have to be a slow unraveling. It can be a powerful reset. But only if the systems meant to support us evolve with us. It’s time to modernize care for women—not by offering more quick fixes, but by rethinking the very foundations of how we listen, diagnose, and heal.


Sunday, May 25, 2025

Unseen Warriors: Cheri Ambrose and the Global Fight Against Male Breast Cancer

By: Lennard M. Goetze, Ed.D

Introduction:
In the vast world of cancer advocacy, few have dared to champion a cause so overlooked, so misunderstood, and so deeply stigmatized. Yet, from the shadows of silence and misdiagnosis emerged a fearless voice—Cheri Ambrose. With unwavering determination and boundless compassion, she has dedicated over a decade to shining a light on a rarely spoken truth: men get breast cancer too. As the founder and driving force behind the Male Breast Cancer Global Alliance, Cheri has transformed personal conviction into a worldwide movement of awareness, support, and lasting change.



Champion of the Voiceless: A Legacy of Bold Compassion

Cheri Ambrose is not a breast cancer survivor herself, but her deep empathy and fierce sense of justice have propelled her to become one of the most important voices in male breast cancer advocacy today. Her story is one of resilience, advocacy, and most of all, humanitarianism. Since 2013, Cheri has committed herself to bringing a voice to those who were silenced by stigma, isolated by fear, or dismissed by systems rooted in bias.

What began as quiet outreach and a desire to fill an information void soon evolved into a full-fledged mission. As she met more men and families grappling with the confusion of a “women’s disease” diagnosis, Cheri saw the devastating effects of societal misunderstanding: late diagnoses, lack of access to clinical trials, emotional alienation, and a complete absence of male representation in public health discussions. For many of these men, Cheri became their first source of validation—and their fiercest advocate.


In 2014, recognizing the urgent need for a centralized resource and community, Cheri founded the Male Breast Cancer Coalition (MBCC), a first-of-its-kind virtual haven for male survivors, caregivers, medical professionals, and advocates. What started as a grassroots initiative quickly gained national attention. The coalition became a beacon for those living in silence, providing not only practical information but also human connection and hope.


By November 2021, the MBCC had grown into a global network, prompting the formation of the Male Breast Cancer Global Alliance (MBCGA). This evolution reflected both the rising number of voices joining the cause and the growing credibility of Cheri’s leadership in the medical and advocacy communities. MBCGA expanded its focus to include not just support, but also scientific collaboration, research advancement, and clinical inclusion. Under Cheri’s guidance, MBCGA now connects survivors, researchers, clinicians, and pharmaceutical leaders from around the world to revolutionize care for men with breast cancer.

Cheri’s humanitarian work doesn’t stop at awareness—it takes tangible form in systemic change. She has been a leading force in persuading pharmaceutical companies to include men in the labeling of breast cancer medications once thought suitable only for women. Through persistence and strategic partnerships, she has opened the door for men to be included in clinical trials, long denied to them due to outdated gender assumptions. Her work not only helps save lives—it rewrites the rules of inclusion in modern medicine.

Advertisement
Mentoring a Movement & Shaping the Next Generation of Advocates
More than an advocate, Cheri is a mentor and mobilizer. She has trained and developed hundreds of survivor representatives—men who now share their stories in hospitals, classrooms, government hearings, and international summits. These men, once voiceless, are now empowered leaders in their own right, thanks to Cheri’s vision and coaching. Their voices form a chorus that breaks through stigma, reshaping public understanding one conversation at a time.

In recognition of her tireless work, Cheri was awarded the Heart of Advocacy honor by the National Consortium of Breast Centers. This prestigious award reflects not just her achievements, but the genuine passion and humanity she brings to every aspect of her mission.

Beyond advocacy, Cheri plays a critical role in the broader cancer awareness movement. As Co-Editor of the New York Cancer Resource Alliance (NYCRA), she contributes to and curates a variety of health and wellness publications including Prevention101.org, NYCRA News, Health Scan News, and First Responders Health Report. Her writing and editorial work amplify her mission, reaching a wide array of professionals, patients, and policy-makers with essential health information and survivor stories.

Cheri is also a graduate of the National Breast Cancer Coalition’s PROJECT LEAD program, and she continues to serve as a key presence at major health summits such as the National Comprehensive Cancer Network Summit, ASCO, SABCS, and the ABC Global Conference in Lisbon. At each of these platforms, she represents not only male breast cancer patients, but all those fighting for recognition and equality in healthcare.

Building a Global Network of Support
Under Cheri Ambrose's leadership, the MBCGA has cultivated a robust network of partnerships with organizations dedicated to providing comprehensive support for men diagnosed with breast cancer. These collaborations aim to address the multifaceted needs of patients, from emotional support to financial assistance.

Financial Assistance through The CARE Project
Recognizing the financial burdens that often accompany a cancer diagnosis, the MBCGA partners with The CARE Project, Inc., a nonprofit organization founded by a breast cancer survivor. The CARE Project's MEN 2 Program offers financial assistance to male breast cancer patients, covering essential expenses such as insurance co-pays, utilities, rent, groceries, fuel, and transportation to and from treatment. This support allows patients to focus on healing without the added stress of financial hardship. 

Educational Resources and Awareness Campaigns
To promote early detection and awareness, the MBCGA has developed multilingual Self-Exam Cards for Men, available in nine languages, including English, Spanish, French, Italian, Dutch, German, Portuguese, Hebrew, and Polish. These cards provide easy-to-follow diagrams and instructions, highlighting warning signs and risk factors specific to men. The initiative is supported by pharmaceutical companies such as Daiichi Sankyo, Inc., Lilly, and Pfizer.

The MBCGA collaborates with leading healthcare institutions to advance research and clinical trials focused on male breast cancer. By bringing together patients, researchers, clinicians, and oncologists, the alliance aims to improve treatment options and outcomes for men diagnosed with the disease. 

In its mission to provide holistic support, the MBCGA partners with organizations such as Imerman Angels, which offers one-on-one support to cancer patients and caregivers through a network of trained Mentor Angels. These mentors provide emotional support and guidance, helping patients navigate their cancer journey. Additionally, the alliance collaborates with Learn Look Locate, an organization dedicated to breast cancer education and support. Together, they work to increase awareness, provide educational resources, and connect patients with support networks. 


Conclusion:

Cheri Ambrose’s legacy is not defined by accolades or titles—it is defined by lives changed, silences broken, and injustices righted. In a world where the voices of the marginalized are often drowned out, she has become a force of amplification. Her compassion is bold. Her fight is personal. Her impact is global.

She has stood up for those who were told they didn’t belong in the breast cancer narrative, and through her, they now have not only a place—but a platform. From living rooms to research labs, from local communities to international health councils, Cheri has made one thing clear: breast cancer doesn’t discriminate, and neither should we.

Cheri Ambrose is more than an advocate. She is a changemaker, a humanitarian, and a beacon of hope for those navigating the darkest moments of their lives. In giving a voice to the voiceless, she has forever changed the story of male breast cancer—for the better.


_________________________________________________________________________________

Sponsor


For more information about the MALE BREAST CANCER GLOBAL ALLIANCE PREDISPOSITION TESTING PROGRAM, contact us at: www.mbcglobalalliance.org or contact our hotline at: 516.522-0777


 --------------------------------------------------------------------------------------------------------------------------

THIS MESSAGE IS BROUGHT TO YOU BY THE MALE BREAST CANCER GLOBAL ALLIANCE

The Male Breast Cancer Global Alliance (MBCGA) is leading the charge in awareness, education, and support for men affected by this disease. This organization has built a worldwide network of survivors, advocates, researchers, and healthcare professionals working to shatter the stigma and silence surrounding male breast cancer. They’ve played a crucial role in pushing for more inclusive research, advancing public health messaging, and ensuring men have access to the resources they need. Through tireless advocacy and collaboration, MBCGA has helped get male breast cancer recognized in global cancer policy and has elevated the voices of countless survivors. Their data-driven campaigns and survivor-led storytelling have reached millions, and their partnership with Bard Diagnostics is all about scaling that impact through accessible genetic testing.

  --------------------------------------------------------------------------------------------------------------------------

RELATED RESOURCES

Under a dedicated partnership with the Male Breast Cancer Global Alliance, BARDDIAGNOSTICS established key programs including: EARLIER DETECTION, PREDISPOSITION GENE TESTING, FIGHT RECURRENCE, ACTIVE SURVEILLANCE AND THE 2ND OPINION SCAN. For the many MEN who seek a significantly improved lifestyle or an upgrade in personalized healthcare, getting better answers about your state of health is paramount and IT ALL STARTS WITH STATE OF THE ART DIAGNOSTICS
. The visionary paradigm that makes up true personalized medical care involves the integration between modalities, a collaboration between specialists and an upgrade in their strategic approach and you'll find it all at BardDiagnostics. 

 --------------------------------------------------------------------------------------------------------------------------

UNCOVERED – Shedding Light on Male Breast Cancer
The first official newsletter from the Male Breast Cancer Global Alliance, launched in proud partnership with AngioMedical Media and the Integrative Cancer Resource Society. Rooted in the belief that education is powerUNCOVERED delivers essential news, scientific updates, and survivor stories to inform and inspire. Each issue is packed with the latest in male breast cancer research, treatment innovations, and advocacy efforts from around the globe. Whether you're a patient, caregiver, or medical professional, UNCOVERED is your trusted source for facts and forward-thinking perspectives. Join us in uncovering the truth—and empowering lives through knowledge. (visit our regularly updated Newsletter)

 --------------------------------------------------------------------------------------------------------------------------

The INTEGRATIVE CANCER RESOURCE SOCIETY is a self-funded (Linkedin Based) independent volunteer group of non-profit foundations/charities, researchers, educators, community leaders and survivors. Under the spirit of collaboration and partnership, we are joined to bring a new level of support to cancer patients, survivors and all those seeking current information about cancer care. We form a unique network of support for one another- while driven to help those who need additional resources, technical updates or empowerment on the road to recovery. ICRS uses the power of the "interweb" to reach a global audience and a network of resources beyond our local borders. We have engaged some of the most impressive minds, perspectives and resources and enjoyed the exchange of vital information that is useful to all. Thanks in part to digital collaboration, these "foreign" connections have always been a part of our cancer crusade, now joining us in what we call "BORDERLESS MEDICINE".

 --------------------------------------------------------------------------------------------------------------------------



In great support of a the global movement of NON-INVASIVE medicine, we proudly introduce the INTEGRATIVE HEALTH RESEARCH CENTER by AngioInnovation Research (501c3). This New York city-based diagnostic imaging validation lab is established to clinically identify the efficacy, performance and supportive claims set by non-invasive therapeutics and diagnostic solutions. Co-founded by Dr. Robert L. Bard, the IHRC offers a non-profit, non-commercialized testing option for health-related innovations who seek an independent and impartial reporting through single-case pilot studies or IRB-Based clinical trials. The IHRC employs credentialed medical professionals and specialists in clinical research whose experience contributes to the unique strategic approach of each test study. (Visit: the AngioInstitute website)

CH10: READING BETWEEN THE ECHOES

THE EYE WITHIN UNLOCKING THE HIDDEN LANGUAGE OF MEDICAL IMAGING By: Lennard M. Goetze, Ed.D   In an age when medical imaging technologie...